The novel alkylating prodrug J1 : diagnosis directed activity profile ex vivo and combination analyses in vitro
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells
A novel quinoline, MT477 : suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma : a National Cancer Institute of Canada Clinical Trials Group trial
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma : A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFκB and Bcl-XL
PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo